News articles about Qiagen (NASDAQ:QGEN) have been trending positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Qiagen earned a news impact score of 0.32 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.7518953100903 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
QGEN has been the subject of several recent analyst reports. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a report on Wednesday, November 8th. Zacks Investment Research downgraded Qiagen from a “buy” rating to a “hold” rating in a report on Monday, October 16th. DZ Bank reissued a “neutral” rating on shares of Qiagen in a report on Monday, August 28th. Cowen reissued a “hold” rating and issued a $33.00 price target on shares of Qiagen in a report on Thursday, September 28th. Finally, Commerzbank reissued a “buy” rating on shares of Qiagen in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $34.06.
Shares of Qiagen (NASDAQ QGEN) traded down $0.22 during trading hours on Tuesday, hitting $31.02. The stock had a trading volume of 667,264 shares, compared to its average volume of 963,111. Qiagen has a 1 year low of $27.51 and a 1 year high of $36.34. The stock has a market capitalization of $7,210.00, a PE ratio of 25.75, a price-to-earnings-growth ratio of 1.94 and a beta of 1.10. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33.
COPYRIGHT VIOLATION WARNING: “Qiagen (QGEN) Earning Favorable Media Coverage, Report Shows” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/05/qiagen-qgen-earning-favorable-media-coverage-report-shows.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
What are top analysts saying about Qiagen N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Qiagen N.V. and related companies.